In non-cancerous mice with NASH, anti-PD1 treatment could lead to increased liver CD8+PD1+ T cells, aggravated liver damage, and increased tumor incidence. This evidence concerns the gene PDCD1 and metabolic dysfunction-associated steatohepatitis.